0.06Open0.06Pre Close0 Volume160 Open Interest4.00Strike Price0.00Turnover118.35%IV46.57%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type0.1533Delta0.2758Gamma46.17Leverage Ratio-0.0041Theta0.0002Rho7.08Eff Leverage0.0017Vega
CureVac Stock Discussion
at ESMO 2024 Congress
TÜBINGEN, Germany/BOSTON, USA – September 9, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first clinical data from CureVac’s ongoing Phase 1 CVGBM cancer vaccine study in patients with rese...
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study
in Patients with Resected Glioblastoma
·First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM
·Part B expected to include up to 20 patients to generate extended data on safety, tolerabil...
Benzinga· 1 min ago
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics.
First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent liti...
No comment yet